Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen
- PMID: 20519939
- DOI: 10.4161/hv.6.6.11709
Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen
Abstract
A good immunogen was developed as an effective recombinant vaccine candidate that protected mice against botulinum neurotoxin serotype B (BoNT/B) intoxication. The Hc fragment of Clostridium botulinum neurotoxin type B (rBoNT/B-Hc) was cloned into the bacterial expression vector pQE-30, and the resulting vector was successfully expressed in the Escherichia coli M15 strain. The purified rBoNT/B-Hc protein was used to vaccinate mice and evaluate their survival against challenge with native BoNT/B. The mice that received three subcutaneous injections of rBoNT/B-Hc immunogen doses ranging from 0.25 to 6.25 μg mixed with Freund's adjuvant were completely protected against an intraperitoneal (i.p.) administration of 10,000 50% lethal doses (LD50) of BoNT/B. A dose response was observed in both the ELISA antibody titers and protective efficacy with increasing dose of immunogen. The work presented here demonstrates that the purified rBoNT/B-Hc was a highly effective immunogen and able to protect against a high-dose neurotoxin challenge.
Similar articles
-
Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.Clin Vaccine Immunol. 2008 Dec;15(12):1819-23. doi: 10.1128/CVI.00239-08. Epub 2008 Oct 8. Clin Vaccine Immunol. 2008. PMID: 18845829 Free PMC article.
-
Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.Immunopharmacol Immunotoxicol. 2009 Jun;31(2):261-6. doi: 10.1080/08923970802438433. Immunopharmacol Immunotoxicol. 2009. PMID: 18932057
-
Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.Anaerobe. 2016 Aug;40:58-62. doi: 10.1016/j.anaerobe.2016.05.012. Epub 2016 May 25. Anaerobe. 2016. PMID: 27236078
-
Development of vaccines for prevention of botulism.Biochimie. 2000 Sep-Oct;82(9-10):955-66. doi: 10.1016/s0300-9084(00)01173-1. Biochimie. 2000. PMID: 11086225 Review.
-
Botulinum neurotoxin vaccines: Past history and recent developments.Hum Vaccin. 2009 Dec;5(12):794-805. doi: 10.4161/hv.9420. Epub 2009 Dec 1. Hum Vaccin. 2009. PMID: 19684478 Review.
Cited by
-
An Ultrasensitive Gold Nanoparticle-based Lateral Flow Test for the Detection of Active Botulinum Neurotoxin Type A.Nanoscale Res Lett. 2017 Dec;12(1):227. doi: 10.1186/s11671-017-1944-9. Epub 2017 Mar 29. Nanoscale Res Lett. 2017. PMID: 28359137 Free PMC article.
-
Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.Hum Vaccin Immunother. 2015;11(2):468-73. doi: 10.4161/hv.29714. Hum Vaccin Immunother. 2015. PMID: 25483668 Free PMC article.
-
Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.Mol Ther Methods Clin Dev. 2014 Oct 1;1:14046. doi: 10.1038/mtm.2014.46. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015984 Free PMC article.
-
Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.Hum Vaccin Immunother. 2019;15(3):755-760. doi: 10.1080/21645515.2018.1547613. Epub 2018 Dec 4. Hum Vaccin Immunother. 2019. PMID: 30433836 Free PMC article.
-
Truncated abrin A chain expressed in Escherichia coli: a promising vaccine candidate.Hum Vaccin Immunother. 2014;10(9):2648-55. doi: 10.4161/hv.29645. Epub 2014 Nov 17. Hum Vaccin Immunother. 2014. PMID: 25483485 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical